About Transcription factor AP-2-beta
Transcription factor AP-2-beta (TFAP2B) is a protein
from Homo sapiens identified by UniProt accession
Q92481, 460 residues long.
MolForge cross-references it against 0 known binders and
434 disease associations.
Target properties
| Protein name | Transcription factor AP-2-beta |
| UniProt accession | Q92481 |
| Gene | TFAP2B |
| Organism | Homo sapiens |
| Length | 460 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (434)
Diseases linked to this target (Open Targets).
- Char syndrome · score 0.80
- patent ductus arteriosus 2 · score 0.61
- body mass index · score 0.53
- lean body mass · score 0.51
- type 2 diabetes mellitus · score 0.50
- body fat percentage · score 0.50
- obesity · score 0.49
- physical activity measurement · score 0.49
- fat body mass · score 0.48
- waist circumference · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92481-F1 | alphafold | PREDICTED | 66.05 | — |
Amino-acid sequence (460 residues)
MHSPPRDQAA IMLWKLVENV KYEDIYEDRH DGVPSHSSRL SQLGSVSQGP YSSAPPLSHT PSSDFQPPYF PPPYQPLPYH QSQDPYSHVN DPYSLNPLHQ PQQHPWGQRQ RQEVGSEAGS LLPQPRAALP QLSGLDPRRD YHSVRRPDVL LHSAHHGLDA GMGDSLSLHG LGHPGMEDVQ SVEDANNSGM NLLDQSVIKK VPVPPKSVTS LMMNKDGFLG GMSVNTGEVF CSVPGRLSLL SSTSKYKVTV GEVQRRLSPP ECLNASLLGG VLRRAKSKNG GRSLRERLEK IGLNLPAGRR KAANVTLLTS LVEGEAVHLA RDFGYICETE FPAKAVSEYL NRQHTDPSDL HSRKNMLLAT KQLCKEFTDL LAQDRTPIGN SRPSPILEPG IQSCLTHFSL ITHGFGAPAI CAALTALQNY LTEALKGMDK MFLNNTTTNR HTSGEGPGSK TGDKEEKHRK
Explore Transcription factor AP-2-beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets